Announcements
- Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
- Hofseth Biocare ASA: Annual General Meeting completed
- Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
- Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
- Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
- Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
- Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
- Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
More ▼
Key statistics
As of last trade Hofseth Biocare ASA (HBQ:FRA) traded at 0.163, 6.19% above its 52-week low of 0.1535, set on Apr 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.163 |
---|---|
High | 0.163 |
Low | 0.163 |
Bid | 0.1635 |
Offer | 0.201 |
Previous close | 0.185 |
Average volume | 1.18k |
---|---|
Shares outstanding | 395.08m |
Free float | 165.07m |
P/E (TTM) | -- |
Market cap | 829.67m NOK |
EPS (TTM) | -0.2449 NOK |
Data delayed at least 15 minutes, as of May 24 2024 08:38 BST.
More ▼